Modality
ADC
MOA
Anti-Tau
Target
TIGIT
Pathway
Checkpoint
CeliacOCDSMA
Development Pipeline
Preclinical
~Apr 2019
→ ~Jul 2020
Phase 1
~Oct 2020
→ ~Jan 2022
Phase 2
~Apr 2022
→ ~Jul 2023
Phase 3
Oct 2023
→ Oct 2025
Phase 3Current
NCT05514905
65 pts·SMA
2023-10→2025-10·Terminated
65 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-10-265mo agoPh3 Readout· SMA
Trial Timeline
Q42024Q2Q3Q42025Q2Q3Q4
P3
Termina…
Catalysts
Ph3 Readout
2025-10-26 · 5mo ago
SMA
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05514905 | Phase 3 | SMA | Terminated | 65 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| BGN-3305 | BeiGene | Phase 2 | BCMA |